Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.43 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.38 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.38 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.38 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.38 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.38 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.38 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.38 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.38 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.38 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.38 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.38 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011929 | 0.99 | HTR1A (0.44) | HTR1AAPEX1BLMALDH1A1HCAR3 | |
| SCHEMBL13618631 | 0.91 | HTR1A (0.43) | HTR1AAPEX1BLMALDH1A1HCAR3 | |
| SCHEMBL13623334 | 0.89 | HTR1A (0.43) | HTR1AAPEX1BLMALDH1A1HCAR3 | |
| SCHEMBL2011768 | 0.85 | DRD2 (0.43) | HTR1AALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL13930337 | 0.81 | ALDH1A1 (0.51) | HTR1AAPEX1BLMALDH1A1KDM4E | |
| SCHEMBL8172704 | 0.81 | FBP1 (0.49) | ALDH1A1MEN1KMT2ACYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL2012002 | 0.80 | TDP1 (0.50) | HTR1AAPEX1BLMALDH1A1KMT2A | |
| SCHEMBL4739129 | 0.79 | HTR1A (0.48) | HTR1AAPEX1BLMKDM4ELMNA | |
| SCHEMBL7292776 | 0.79 | HTR1A (0.46) | HTR1AAPEX1BLMALDH1A1KDM4E | |
| SCHEMBL3841214 | 0.79 | TDP1 (0.51) | HTR1AAPEX1BLMALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513055-A1 | PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF | Pharmathen S.A. (GR) | 2012-10-24 | — | — | EP | claimed |
| US-20120253051-A1 | PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2012-10-04 | — | — | US | claimed |
| WO-2011072704-A1 | PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2011-06-23 | — | — | WO | claimed |
| US-7619095-B2 | Process for the preparation of indolone derivative | ALEMBIC LIMITED (IN) | 2009-11-17 | — | — | US | claimed |
| EP-1848691-B1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LTD (IN) | 2009-11-11 | — | — | EP | claimed |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | ALEMBIC LIMITED (IN) | 2008-10-23 | — | — | US | claimed |
| EP-1848691-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | Alembic Limited (IN) | 2007-10-31 | — | — | EP | claimed |
| WO-2006123356-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LIMITED (IN) | 2006-11-23 | — | — | WO | claimed |
| CN-116262706-A | Preparation process of ropinirole intermediate | 浙江华海药业股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-2513055-A1 | PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF | Pharmathen S.A. (GR) | 2012-10-24 | — | — | EP | disclosed |
| US-20120253051-A1 | PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2012-10-04 | — | — | US | disclosed |
| US-7968731-B2 | Process for the purification of Ropinirole hydrochloride | ALEMBIC LIMITED (IN) | 2011-06-28 | — | — | US | disclosed |
| WO-2011072704-A1 | PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2011-06-23 | — | — | WO | disclosed |
| US-7863462-B2 | Process for the purification of ropinirole hydrochloride | ALEMBIC LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| WO-2007010557-A2 | PROCESS FOR THE PREPARATION OF HIGHLY PURE ROPINIROLE | IND-SWIFT LABORATORIE LIMTED (IN) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006123356-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LIMITED (IN) | 2006-11-23 | — | — | WO | disclosed |
| EP-0113964-B1 | 4-AMINOALKYL-2(3H)-INDOLONES | SMITHKLINE BECKMAN CORPORATION (US) | 1986-10-22 | — | — | EP | disclosed |
| US-4588740-A | Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones | SMITHKLINE BECKMAN CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0113964-A1 | 4-Aminoalkyl-2(3H)-indolones | SMITHKLINE BECKMAN CORPORATION (US) | 1984-07-25 | — | — | EP | disclosed |
| US-4452808-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | HTR3C, HTR3B, HTR1B | HTR1A 16/4885CHRM2 695/4885ADRA2A 430/4885 |
| US-20120253051-A1 | PROCESS FOR THE PREPARATION OF ROPINIROLE AND SALTS THEREOF | PRLHR, ADCYAP1R1, REN | HTR1A 792/4885CHRM2 2358/4885ADRA2A 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.